AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
May 17, 2023 14:15 ET
|
AB Science
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 2023 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May, 2023, 8:00pm CET AB Science SA...
AB Science résume les messages clés de sa participation à une table ronde lors du ALS Drug Development Summit 2023
May 17, 2023 14:15 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE RÉSUME LES MESSAGES CLÉS DE SA PARTICIPATION À UNE TABLE RONDE LORS DU ALS DRUG DEVELOPMENT SUMMIT 2023 (BOSTON, ETATS-UNIS) Paris, 17 mai 2023, 20h00 AB Science SA...
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
May 09, 2023 12:06 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE...
AB Science annonce que Health Canada a repris la revue du dossier d’enregistrement du masitinib dans la sclérose latérale amyotrophique, suite à l’examen préliminaire de la réponse soumise par AB Science
May 09, 2023 12:06 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE HEALTH CANADA A REPRIS LA REVUE DU DOSSIER D’ENREGISTREMENT DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE, SUITE A L’EXAMEN PRELIMINAIRE DE LA...
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
April 25, 2023 15:52 ET
|
Muscular Dystrophy Association
New York, April 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the...
Muscular Dystrophy Association Announces Programming for ALS Awareness Month
April 24, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, April 24, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced programming and fundraising events in support of people living with Amyotrophic Lateral...
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
April 18, 2023 12:55 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES MASITINIB PATENT GRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2037 TO...
AB Science annonce l’obtention d’un brevet sur le masitinib au Japon pour le traitement de la sclérose latérale amyotrophique, renforçant ainsi la position de la société en matière de propriété intellectuelle jusqu’en 2037
April 18, 2023 12:55 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'OBTENTION D'UN BREVET SUR LE MASITINIB AU JAPON POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, RENFORÇANT AINSI LA POSITION DE LA SOCIÉTÉ EN...
Amyotrophic Lateral Sclerosis Treatment Market Sales to Reach US$ 1021 Million in 2032 | CAGR of 5.6%
April 14, 2023 08:50 ET
|
Market.Us
New York, April 14, 2023 (GLOBE NEWSWIRE) -- The global Amyotrophic Lateral Sclerosis Treatment Market was valued at US$ 600 million in 2022 and is expected to grow US$ 1021 million in 2032. Between...
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
April 12, 2023 12:23 ET
|
AB Science
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL...